Evidence map›Paper›PMID 37914719›Full record

ArticleNature communications2023

Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides.

Olena S Tokareva, Kunhua Li, Tara L Travaline, Ty M Thomson, Jean-Marie Swiecicki, Mahmoud Moussa, Jessica D Ramirez, Sean Litchman, Gregory L Verdine, John H McGee

Abstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olena S Tokareva *FOG Pharmaceuticals Inc., Cambridge, MA, USA.
Kunhua Li *FOG Pharmaceuticals Inc., Cambridge, MA, USA.ORCID 0000-0002-9139-4257
Tara L TravalineFOG Pharmaceuticals Inc., Cambridge, MA, USA.ORCID 0000-0002-7218-8650
Ty M ThomsonFOG Pharmaceuticals Inc., Cambridge, MA, USA.ORCID 0000-0002-9109-4596
Jean-Marie SwiecickiFOG Pharmaceuticals Inc., Cambridge, MA, USA.ORCID 0000-0002-7139-8621
Mahmoud MoussaFOG Pharmaceuticals Inc., Cambridge, MA, USA.
Jessica D RamirezFOG Pharmaceuticals Inc., Cambridge, MA, USA.ORCID 0000-0002-7912-9506
Sean LitchmanFOG Pharmaceuticals Inc., Cambridge, MA, USA.ORCID 0009-0001-9622-4193
Gregory L VerdineFOG Pharmaceuticals Inc., Cambridge, MA, USA. gregory_verdine@harvard.edu.ORCID 0000-0002-2195-364X
John H McGeeFOG Pharmaceuticals Inc., Cambridge, MA, USA. jmcgee@fogpharma.com.ORCID 0000-0002-3440-5247

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecules that induce novel interactions between proteins hold great promise for the study of biological systems and the development of therapeutics, but their discovery has been limited by the complexities of rationally designing interactions between three components, and because known binders to each protein are typically required to inform initial designs. Here, we report a general and rapid method for discovering α-helically constrained (Helicon) polypeptides that cooperatively induce the interaction between two target proteins without relying on previously known binders or an intrinsic affinity between the proteins. We show that Helicons are capable of binding every major class of E3 ubiquitin ligases, which are of great biological and therapeutic interest but remain largely intractable to targeting by small molecules. We then describe a phage-based screening method for discovering "trimerizer" Helicons, and apply it to reprogram E3s to cooperatively bind an enzyme (PPIA), a transcription factor (TEAD4), and a transcriptional coactivator (β-catenin).

Indexed as

PeptidesUbiquitin-Protein LigasesUbiquitinationPeptidesUbiquitin-Protein Ligases

Identifiers

PMID37914719
PMCPMC10620186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.